CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Patients With Advanced Chemorefractory Solid Tumors

ABSTRACT: This phase II trial tests how well CPI-613 (devimistat) in combination with hydroxychloroquine (HCQ) and 5-fluorouracil (5-FU) or gemcitabine works in patients with solid tumors that may have spread from where they first started to nearby tissue, lymph nodes, or distant parts of the body (advanced) or that have not responded to chemotherapy medications (chemorefractory). Metabolism is how the cells in the body use molecules (carbohydrates, fats, and proteins) from food to get the energy they need to grow, reproduce and stay healthy. Tumor cells, however, do this process differently as they use more molecules (glucose, a type of carbohydrate) to make the energy they need to grow and spread. CPI-613 works by blocking the creation of the energy that tumor cells need to survive, grow in the body and make more tumor cells. When the energy production they need is blocked, the tumor cells can no longer survive. Hydroxychloroquine is a drug used to treat malaria and rheumatoid arthritis and may also improve the immune system in a way that tumors may be better controlled. Fluorouracil is in a class of medications called antimetabolites. It works by killing fast-growing abnormal cells. Gemcitabine is a chemotherapy drug that blocks the cells from making DNA and may kill tumor cells. CPI-613 (devimistat) in combination with hydroxychloroquine and 5-fluorouracil or gemcitabine may work to better treat advanced solid tumors.

DISEASE(S): Metastatic Gastroesophageal Junction Adenocarcinoma,Adenocarcinoma,Refractory Lung Adenocarcinoma,Carcinoma,Carcinoma, Transitional Cell,Advanced Ovarian Carcinoma,Metastatic Colorectal Carcinoma,Lung Neoplasms,Clinical Stage Iv Gastroesophageal Junction Adenocarcinoma Ajcc V8,Stage Iii Pancreatic Cancer Ajcc V8,Esophageal Neoplasms,Stage Iv Ovarian Cancer Ajcc V8,Colorectal Neoplasms,Advanced Lung Adenocarcinoma,Refractory Ovarian Carcinoma,Ovarian Neoplasms,Pancreatic Neoplasms,Advanced Gastroesophageal Junction Adenocarcinoma,Stage Iv Pancreatic Cancer Ajcc V8,Refractory Biliary Tract Carcinoma,Refractory Urothelial Carcinoma,Stage Iii Lung Cancer Ajcc V8,Stage Iii Ovarian Cancer Ajcc V8,Stage Iv Colorectal Cancer Ajcc V8,Refractory Gastroesophageal Junction Adenocarcinoma,Clinical Stage Iii Gastroesophageal Junction Adenocarcinoma Ajcc V8,Metastatic Ovarian Carcinoma,Metastatic Lung Adenocarcinoma,Advanced Colorectal Carcinoma,Advanced Malignant Solid Neoplasm,Advanced Pancreatic Carcinoma,Stage Ii Pancreatic Cancer Ajcc V8,Metastatic Pancreatic Carcinoma,Metastatic Urothelial Carcinoma,Carcinoma, Ovarian Epithelial,Advanced Biliary Tract Carcinoma,Stage Iii Colorectal Cancer Ajcc V8,Metastatic Biliary Tract Carcinoma,Adenocarcinoma Of Lung,Stage Iv Lung Cancer Ajcc V8,Refractory Pancreatic Carcinoma,Refractory Colorectal Carcinoma,Advanced Urothelial Carcinoma

PROVIDER: 8718 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR